Dr Fabiola Valvert speaks to ecancer about a retrospective multinational analysis of clinical features, therapeutic approaches and outcomes from the Latin American Group of Lymphoproliferative Disorders (GELL).

Extranodal NK/T-cell lymphoma (ENKTL) is a rare subtype of Epstein-Barr virus (EBV)-related non-Hodgkin lymphoma

This study's objective was to fill the knowledge gap regarding ENKTL in LATAM, by analysing the clinical features, therapeutic approaches, and outcomes of patients with ENKTL in this region.

The study analyses 303 patients, revealing that 88% receive first-line treatments like chemotherapy and radiotherapy.

Survival rates stand at 59%, with advanced-stage patients facing worse outcomes.

Key challenges include progression, infection, and limited access to chemotherapy.

The research highlights the importance of early detection and ongoing advocacy for better clinical trial participation.